P1.124. Clinical Outcomes of Esophageal Cancer With Lymph Node Metastasis Invasion Into Other Organs (T4LN)

Clicks: 7
ID: 325743
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #397 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Oncology/Radiation Therapy Background The standard treatment for T4 esophageal cancer without distant metastasis is definitive chemoradiotherapy (dCRT). In the Japanese Classification of Esophageal Cancer, 12th Edition, T4 refers to both primary tumor invasion into adjacent organs (T4ESO) and also lymph node metastasis invasion into other organs (T4LN). However, comprehensive data and reports on T4LN are scarce. This study aimed to compare the clinical outcomes of T4ESO and T4LN cases and identify prognostic factors. Methods We evaluated patients diagnosed with T4 thoracic esophageal squamous cell carcinoma who underwent definitive CRT (cisplatin + 5-FU with concurrent radiotherapy, dCRT) at our hospital between May 2007 and August 2021. The patients were categorized into T4ESO and T4LN groups. We retrospectively analyzed overall survival (OS) of each group, and examined the prognostic factors. Results A total of 153 patients (110 in the T4ESO group and 43 in the T4LN group) were included, with a median age of 66 years. The OS rates (T4ESO vs. T4LN) at 1, 2, and 3 years were 74.0% vs. 77.5%, 54.5% vs. 31.8%, and 43.7% vs. 28.9%, respectively. The median survival time was 2.2 years versus 1.2 years (HR 1.81; 95% CI 1.18–2.78). In the multivariate analysis, Performance Status (PS) ≥ 1, T4LN, and Hb < 13.0 g/dL were identified as independent poor prognostic factors. Conclusion Among patients with T4 esophageal cancer treated with dCRT, those with T4LN had a poorer prognosis than those with T4ESO. There is an urgent need to develop more intensive multidisciplinary therapies and novel treatment strategies specifically for T4LN cases.
Reference Key
openalex_W7203875503 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aya Ueda, Katsuyuki Sakanaka, Shinya Hiraoka, Ryo Narukami, Motoo Nomura, Chikatoshi Katada, Akira Yokoyama, Masashi Tamaoki, Shigeru Tsunoda, Manabu Muto
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.272
URL
https://doi.org/10.1093/dote/doag077.272
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.